Evidence map›Paper›PMID 15286725›Full record

ReviewNature reviews. Immunology2004

Fibrotic disease and the T(H)1/T(H)2 paradigm.

Thomas A Wynn

Abstract readReview
In one paragraph

Review in Nature reviews. Immunology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 831 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
831citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

831 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Trial
  7. Review
  8. Review
  9. Time-Dependent Efficacy of Lymphaticovenous Anastomosis in Secondary Lymphedema: A Rabbit Model Study.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. CD8MedComm · 2026
    Review
  19. An Overview of IgG4-Related Disease.Archives of internal medicine research · 2026
    Article
  20. Review

771 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Thomas A WynnLaboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, Room 6154, MSC 8003, Bethesda, Maryland 20892, USA. twynn@niaid.nih.gov

Funding

Immunological Intervention In SchistosomiasisZ01AI000829 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI WYNN, THOMAS · 1998 to 2008
$3.4M
Mechanisms of Fibrosis in Asthma and Other Fibroproliferative DiseasesZ01AI001019 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI WYNN, THOMAS · 2007 to 2008
$635k
Intramural NIH HHS Z01 AI000829Intramural NIH HHS Z01 AI001019
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsChemokinesFibroblastsFibrosisHumansInterleukin-13MacrophagesTh1 CellsTh2 CellsTransforming Growth Factor betaChemokinesInterleukin-13Transforming Growth Factor beta

Identifiers

PMID15286725
PMCPMC2702150

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.